Wet Age-Related Macular Degeneration (AMD) Market And its Growth prospect in the Near Future

1. Wet Age-Related Macular Degeneration Market to Reach $10.4 Billion by 2024

2. The market is predominantly driven by the increase in prevalence of AMD, lack of availability of specific treatment, and surge in geriatric population, according to P&S Intelligence. Lucentis, Eylea, and Avastin are the key drugs available globally for the management of wet AMD. Among these, Eylea is expected to dominate the market during the forecast period. Increasing prevalence of AMD and rise in demand for Eylea are some of the major factors propelling the demand for this drug in the wet age-related macular degeneration market. Based on the route of administration, the wet age-related macular degeneration market is bifurcated into intravitreally and intravenously administered drugs. During the forecast period, the market is expected to witness faster growth in the category of drugs administered through the intravitreal route, with 7.2% CAGR. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/wet-age-related-macular-degeneration-market “

3. Geographically, North America holds the largest share in the wet age-related macular degeneration market, with an estimated revenue contribution of around $3.0 billion in 2018. Rising prevalence of wet AMD, growing number of drug approvals, and extensive presence of key players in the region are the key factors supporting the market growth in North America. During the forecast period, the wet age-related macular degeneration market is expected to witness the fastest growth in APAC, with 8.8% CAGR. The growth in the APAC wet age-related macular degeneration industry is mainly led by the surge in geriatric population, rise in prevalence of AMD, and medical reimbursements provided by the government for the treatment in the region. Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/wet-age-related-macular-degeneration-market/report-sample “

4. Also, since the treatment of wet AMD is quite expensive, government in countries, such as South Korea and Malaysia, have introduced health insurance plans that cover some of the treatment cost to reduce the healthcare burden on people. For instance, under South Korea’s universal government health insurance plan, patients suffering from wet AMD can receive up to 10 injections of ranibizumab during their lifetime. Thus, government initiatives in the form of medical reimbursements are supporting the growth of the wet age-related macular degeneration market in the APAC region. The global wet age-related macular degeneration market is marked by the presence of several large players, such as Regeneron Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Ophthotech Corporation, Kubota Pharmaceutical Holdings Co. Ltd., Gilead Sciences Inc., Novartis AG, Alimera Sciences Inc., and Bayer AG. “

5. THANK YOU! For queries, kindly write to: enquiry@psmarketresearch.com GET IN TOUCH www.psmarketresearch.com B-13, Sector-2, Noida, U.P.-201301, INDIA Contact No: +91 120 4541 337 US/Canada Toll-Free: 1-888-778-7886 US/Canada Toll-Free: 1-888-778-7886